Published in Immunology on February 14, 2011
In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood (2011) 1.63
Organ-specific features of natural killer cells. Nat Rev Immunol (2011) 1.48
NK cells: immune cross-talk and therapeutic implications. Immunotherapy (2011) 0.96
The role of natural killer cells in multiple sclerosis and their therapeutic implications. Front Immunol (2013) 0.91
Natural killer cells and their receptors in multiple sclerosis. Brain (2012) 0.87
Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis. PLoS One (2012) 0.86
The viral KSHV chemokine vMIP-II inhibits the migration of Naive and activated human NK cells by antagonizing two distinct chemokine receptors. PLoS Pathog (2013) 0.84
CX3CR1-dependent recruitment of mature NK cells into the central nervous system contributes to control autoimmune neuroinflammation. Eur J Immunol (2016) 0.79
Effect of chemokine receptor CX3CR1 deficiency in a murine model of respiratory syncytial virus infection. Comp Med (2012) 0.79
NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation. Front Immunol (2015) 0.78
The chemokine CX3CL1 (fractalkine) and its receptor CX3CR1: occurrence and potential role in osteoarthritis. Arch Immunol Ther Exp (Warsz) (2014) 0.76
Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents. Mol Neurobiol (2016) 0.75
The biology of human natural killer-cell subsets. Trends Immunol (2001) 10.10
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 8.25
Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood (2001) 5.23
Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood (2010) 3.58
CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood (2010) 3.32
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood (2001) 2.87
CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood (2008) 2.52
Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest Ophthalmol Vis Sci (2007) 2.36
Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res (2001) 2.33
Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest (2001) 2.10
The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J (2004) 2.04
The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J (2006) 2.04
CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood (2009) 1.94
Production and neuroprotective functions of fractalkine in the central nervous system. Brain Res (2003) 1.87
The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci (2006) 1.68
Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. Blood (2007) 1.63
CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells. Blood (2010) 1.63
Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol (2002) 1.62
Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol (2002) 1.55
Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol (2002) 1.53
Regulation of NK cell functions by TGF-beta 1. J Immunol (1995) 1.51
CD27 defines phenotypically and functionally different human NK cell subsets. J Immunol (2008) 1.44
Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol (1998) 1.43
Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J Immunol (2001) 1.34
CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflammation (2005) 1.27
Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood (2008) 1.22
IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. J Allergy Clin Immunol (2003) 1.18
The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors. Arthritis Res Ther (2007) 1.13
Natural killer cells in human autoimmunity. Curr Opin Immunol (2009) 1.11
CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol (1997) 1.10
New developments in understanding and treating neuroinflammation. J Mol Med (Berl) (2008) 1.04
Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood (2007) 1.03
TGF-beta1 upregulates CX3CR1 expression and inhibits fractalkine-stimulated signaling in rat microglia. J Neuroimmunol (2002) 1.01
Fractalkine in rheumatoid arthritis and allied conditions. Mod Rheumatol (2006) 0.97
Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood (2007) 0.97
Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J (2005) 0.94
Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res (2007) 0.92
Fractalkine induces chemotaxis and actin polymerization in human dendritic cells. Inflamm Res (2001) 0.92
Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol (2006) 0.90
Fractalkine in rheumatoid arthritis: a review to date. Rheumatology (Oxford) (2008) 0.88
CCR5, RANTES and CX3CR1 polymorphisms: possible genetic links with acute heart rejection. Transplantation (2005) 0.85
IL-15 and IL-2 oppositely regulate expression of the chemokine receptor CX3CR1. Blood (2003) 0.83
Expression of fractalkine, CX3CR1, and vascular endothelial growth factor in human chronic renal allograft rejection. Transplant Proc (2006) 0.81
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 10.99
Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 8.25
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85
Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov (2007) 6.33
Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron (2012) 5.84
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med (2003) 3.89
The myeloid cells of the central nervous system parenchyma. Nature (2010) 3.80
Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A (2007) 3.61
Identity-by-descent filtering of exome sequence data identifies PIGV mutations in hyperphosphatasia mental retardation syndrome. Nat Genet (2010) 3.60
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One (2010) 3.24
In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity (2010) 3.18
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci (2011) 3.06
The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol (2005) 2.96
Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke (2007) 2.76
Cortical demyelination in PML and MS: Similarities and differences. Neurology (2008) 2.75
Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol (2008) 2.71
Development, maintenance and disruption of the blood-brain barrier. Nat Med (2013) 2.62
The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol (2003) 2.58
Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron (2008) 2.44
Terminally differentiated CD8⁺ T cells negatively affect bone regeneration in humans. Sci Transl Med (2013) 2.43
Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum (2007) 2.42
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40
Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS One (2008) 2.39
Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci (2004) 2.35
Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity (2010) 2.32
Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci U S A (2003) 2.30
Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood (2008) 2.26
CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol (2010) 2.25
Regulation of tau pathology by the microglial fractalkine receptor. Neuron (2010) 2.24
Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog Neurobiol (2007) 2.18
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain (2005) 2.17
Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol (2009) 2.15
Isolation of murine microglial cells for RNA analysis or flow cytometry. Nat Protoc (2006) 2.08
Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J (2005) 2.04
The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J (2006) 2.04
Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol (2012) 2.01
Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron (2005) 2.01
The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol (2011) 1.96
The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J Exp Med (2004) 1.90
Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics (2002) 1.85
Natalizumab and PML. Nat Neurosci (2005) 1.85
Expression of CCR7 in multiple sclerosis: implications for CNS immunity. Ann Neurol (2004) 1.83
MR-elastography reveals degradation of tissue integrity in multiple sclerosis. Neuroimage (2009) 1.83
G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands. Blood (2011) 1.82
Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood (2003) 1.76
Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain (2003) 1.75
The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci (2005) 1.74
Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem (2005) 1.74
The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell (2002) 1.73
Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. Br J Ophthalmol (2011) 1.73
Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol (2002) 1.70
CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat Neurosci (2010) 1.65
Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol (2007) 1.63
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
Deficient CX3CR1 signaling promotes recovery after mouse spinal cord injury by limiting the recruitment and activation of Ly6Clo/iNOS+ macrophages. J Neurosci (2011) 1.59
How to treat tumefactive demyelinating disease? Mult Scler (2013) 1.59
Severe disease, unaltered leukocyte migration, and reduced IFN-gamma production in CXCR3-/- mice with experimental autoimmune encephalomyelitis. J Immunol (2006) 1.59
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther (2002) 1.58
Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain (2005) 1.58
Chemokines and chemokine receptors: multipurpose players in neuroinflammation. Int Rev Neurobiol (2007) 1.56
Microgliosis: the questions shape the answers. Nat Neurosci (2007) 1.51
Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med (2003) 1.47
Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol (2005) 1.46
Novel interferon-beta-induced gene expression in peripheral blood cells. J Leukoc Biol (2007) 1.45
Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol (2005) 1.45
Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol (2004) 1.44
Macrophages recruited via CCR2 produce insulin-like growth factor-1 to repair acute skeletal muscle injury. FASEB J (2010) 1.44
Autoregulation of Th1-mediated inflammation by twist1. J Exp Med (2008) 1.43
Microglial repopulation model reveals a robust homeostatic process for replacing CNS myeloid cells. Proc Natl Acad Sci U S A (2012) 1.43
Cellular immunodepression preceding infectious complications after acute ischemic stroke in humans. Cerebrovasc Dis (2007) 1.42
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther (2002) 1.42
Isolation of brain and spinal cord mononuclear cells using percoll gradients. J Vis Exp (2011) 1.40
The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta (2010) 1.40
Acute skeletal muscle injury: CCL2 expression by both monocytes and injured muscle is required for repair. FASEB J (2011) 1.40
CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem (2011) 1.40
VEGF-mediated inflammation precedes angiogenesis in adult brain. Exp Neurol (2004) 1.39
Stroke propagates bacterial aspiration to pneumonia in a model of cerebral ischemia. Stroke (2006) 1.39
Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol (2011) 1.35
Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics (2007) 1.34
Defining interferon beta response status in multiple sclerosis patients. Ann Neurol (2004) 1.34
Perivascular spaces--MRI marker of inflammatory activity in the brain? Brain (2008) 1.33
Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler (2011) 1.33
Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol (2009) 1.32
Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation and fibrosis in mdx mice. J Neurol Sci (2007) 1.31
Patterns of retinal nerve fiber layer loss in multiple sclerosis patients with or without optic neuritis and glaucoma patients. Clin Neurol Neurosurg (2010) 1.30
Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev (2012) 1.30
TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet (2003) 1.30
Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB J (2009) 1.30